Novartis prunes its pipeline
An actinium-based backup and Werner helicase inhibitor are notable absences.
Roche follows Pfizer out of LTβR
The group also discontinues a mystery asset, and a Tecentriq trial in periadjuvant lung cancer.
Cardiff goes south again
The latest onvansertib data, and an abrupt CEO departure, spook investors.
A first test of OnKure’s mutant-specific gamble
A phase 1 study of OKI-219 reads out imminently.
Moderna investors prepare for a phase 3 reveal
Intismeran autogene’s Interpath-001 trial reads out this year.
One Genmab Rybrevant challenge is rendered moot
GEN1286 looks dead, though MCLA-129 continues for now.
